AI tool outperforms manual PD-L1 scoring in a study
Integrating artificial intelligence into pathology routine workflows could optimise patient selection for immunotherapy
First-in-human trial of a TCR-T therapy targeting KRAS G12V reports a significant response rate
Preliminary results of NW-301V are promising, with a lack of severe adverse effects at all doses tested in patients with pancreatic cancer or colorectal cancer
Novel strategies to overcome resistance to immune checkpoint inhibitors show promise in early studies
Blocking GDF-15, an mRNA-based therapy and targeting VISTA have a strong mechanistic rationale, resulting in clinical benefit in heavily pre-treated patients
A novel off-the-shelf cancer vaccine shows some potential in PD-L1-negative patients with advanced melanoma
Although the phase III investigational study with IO102-IO103 plus pembrolizumab is negative, it offers precious insights to advance research in the field
Promising novel strategies to boost anticancer immunity in NECs
Despite the presentation of encouraging study findings with novel immunotherapy-based therapies, long-term outcomes are needed to better understand the magnitude of clinical benefit and many questions remain around off-target toxicity and the identification of patients most likely to respond to treatment
First-line ivonescimab plus chemotherapy improves progression-free survival in squamous NSCLC
Robust efficacy findings and unexpectedly low haemorrhagic events were observed with the bispecific antibody but results will only change practice if benefits translate into overall survival and are replicated beyond China
Personalised cancer vaccines: the next frontier or an elusive goal?
Although genomics-guided personalised cancer vaccines have demonstrated efficacy in early-phase clinical studies, we are still awaiting the results of larger-scale trials
How connecting the dots could deliver a breakthrough in cancer vaccines
After decades of missed promises, cancer vaccines are likely approaching prime time due to major advances in cancer immunobiology, immunotherapy and biomedical technology
Is thymic health a novel tumour-agnostic biomarker?
Study findings reveal that good thymic health, based on an AI-derived algorithm, is associated with improved survival after immunotherapy in different tumour types
Next-generation CAR-T cells are in the pipeline
Novel approaches are being tested to overcome current challenges in the use of cellular therapies such as high toxicity and a complex manufacturing process